This article will address the topic of Hydroxydione, which has been the subject of interest and debate in various areas. Hydroxydione has aroused the interest of experts and the general public due to its relevance and impact in different areas. Throughout history, Hydroxydione has been the object of study and analysis, which has allowed us to delve deeper into its meaning and significance. In this sense, it is essential to delve into the different approaches and perspectives that exist around Hydroxydione, in order to understand its importance and contribution in the field in which it operates. This article aims to provide a broad and detailed vision of Hydroxydione, providing elements that enrich knowledge and promote a critical and reflective analysis of this topic.
Clinical data | |
---|---|
Trade names | Viadril, Predion, Presuren |
Other names | 21-Hydroxy-5β-pregnane-3,20-dione |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C21H32O3 |
Molar mass | 332.484 g·mol−1 |
3D model (JSmol) | |
| |
|
Hydroxydione, as hydroxydione sodium succinate (INN , USAN , BAN ) (brand names Viadril, Predion, and Presuren), also known as 21-Hydroxy-5β-pregnane-3,20-dione, is a neuroactive steroid which was formerly used as a general anesthetic, but was discontinued due to incidence of thrombophlebitis in patients. It was introduced in 1957, and was the first neuroactive steroid general anesthetic to be introduced for clinical use, an event which was shortly preceded by the observation in 1954 of the sedative properties of progesterone in mice.
Related compounds include alfadolone, alfaxolone, dihydrodeoxycorticosterone, ganaxolone, minaxolone, pregnanolone, and renanolone.